Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP

• Conditions: Paraduodenal pancreatitis; MedDRA version: 12.1Level: LLTClassification code 10009093Term: Chronic pancreatitis

• Registration Number: EUCTR2009-016082-29-BE
• Lead Sponsor: Erasme hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-11-25
• Last Update Posted: 14 October 2013

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with one or several of the following radiological criteria for paraduodenal pancreatitis will be selected to participate to the protocol: an occupying mass lesion in the pancreaticoduodenal groove (hypointense relative to the pancreatic tissue on T1-weighted images and iso or slightly hyperintense on T2-weighted images); duodenal-wall thickening; cysts in the groove or/and duodenal wall.8 Others inclusion criteria will be being 18 years or older and having the capacity to give an informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Exclusion criteria will include a current pregnancy and the evidence of neoplasia (digestive or other).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified